Home / Technology / FDA Approves Groundbreaking Dual Ketone/Glucose Monitor
FDA Approves Groundbreaking Dual Ketone/Glucose Monitor
26 Aug
Summary
- The FDA has authorized Abbott Laboratories' new glucose monitor.
- This device is the first of its kind to track both ketone and blood sugar levels.
- Continuous monitoring of both metrics is now possible with this innovative device.
On August 25, 2026, the U.S. Food and Drug Administration granted authorization for a novel device developed by Abbott Laboratories. This marks a significant milestone in health monitoring technology.
This authorization introduces the first-ever medical device capable of continuously tracking both ketone levels and blood sugar. The dual-monitoring capability offers individuals and healthcare providers unprecedented insights into metabolic health.
The new monitor is expected to enhance disease management and overall wellness by providing a comprehensive, real-time view of these crucial health indicators. This technological advancement promises to streamline patient care and improve health outcomes.
